iwCLL 2019 | Updates from the ERIC: a focus on MRD-guided approaches
Paolo Ghia
• 20 Sep 2019
Paolo Ghia, MD, PhD, IRCCS, San Raffaele Scientific Institute, Milan, Italy, delivers updates from the European Research Initiative on CLL (ERIC) where they’ve focused on measurable residual disease (MRD) with a dedicated workshop having been organized. Prof. Ghia also gives an outline of the IMPROVE study of venetoclax in combination with ibrutinib. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
